Literature DB >> 16034849

Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis.

A Avenell1, W J Gillespie, L D Gillespie, D L O'Connell.   

Abstract

BACKGROUND: Vitamin D and related compounds have been used to prevent fractures.
OBJECTIVES: To determine the effects of vitamin D or analogues, with or without calcium, in the prevention of fractures in older people. SEARCH STRATEGY: We searched the Cochrane Bone, Joint and Muscle Trauma Group trials register, the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 1, 2005), MEDLINE, EMBASE, CINAHL, and reference lists of articles. Most recent search: March 2005. SELECTION CRITERIA: Randomised or quasi-randomised trials comparing vitamin D or an analogue, alone or with calcium, against placebo, no intervention, or calcium, reporting fracture outcomes, in older people. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality, and extracted data. Data were pooled, where admissible, using the fixed-effect model, or random-effects model if the relative risks were heterogeneous. MAIN
RESULTS: Vitamin D alone showed no statistically significant effect on hip fracture (seven trials, 18,668 participants, RR 1.17, 95% CI 0.98 to 1.41), vertebral fracture (four trials, 5698 participants, RR (random effects) 1.13, 95% CI 0.50 to 2.55) or any new fracture (eight trials, 18,903 participants, RR 0.99, 95% CI 0.91 to 1.09). Vitamin D with calcium marginally reduced hip fractures (seven trials, 10,376 participants, RR 0.81, 95% CI 0.68 to 0.96), non-vertebral fractures (seven trials, 10,376 participants, RR 0.87, 95% CI 0.78 to 0.97), but there was no evidence of effect of vitamin D with calcium on vertebral fractures. The effect appeared to be restricted to those living in institutional care. Hypercalcaemia was more common when vitamin D or its analogues was given compared with placebo or calcium (14 trials, 8035 participants, RR 2.38, 95% CI 1.52 to 3.71). The risk was particularly high with calcitriol (three trials, 742 participants, RR 14.94, 95% CI 2.95 to 75.61). There was no evidence that vitamin D increased gastro-intestinal symptoms (seven trials, 10,188 participants, RR (random effects) 1.03, 95% CI 0.79 to 1.36) or renal disease (nine trials, 10,107 participants, RR 0.80, 95% CI 0.34 to 1.87). AUTHORS'
CONCLUSIONS: Frail older people confined to institutions may sustain fewer hip and other non-vertebral fractures if given vitamin D with calcium supplements. Effectiveness of vitamin D alone in fracture prevention is unclear. There is no evidence of advantage of analogues of vitamin D compared with vitamin D. Calcitriol may be associated with an increased incidence of adverse effects. Dose, frequency, and route of administration of vitamin D in older people require further investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034849     DOI: 10.1002/14651858.CD000227.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  45 in total

1.  How much vitamin D should I take?

Authors:  Cathleen S Colón-Emeric; Kenneth W Lyles
Journal:  J Clin Invest       Date:  2012-05       Impact factor: 14.808

Review 2.  Hip fracture.

Authors:  Martyn Parker; Antony Johansen
Journal:  BMJ       Date:  2006-07-01

3.  Calcium-PTH-vitamin D axis in older patients with hip fracture.

Authors:  A A Fisher; M W Davis
Journal:  Osteoporos Int       Date:  2006-11-23       Impact factor: 4.507

4.  Update in women's health.

Authors:  Julie L Mitchell; Jennifer R Zebrack; Susan L Davids; Ann B Nattinger; Joan M Neuner
Journal:  J Gen Intern Med       Date:  2007-06-05       Impact factor: 5.128

5.  High-dose oral vitamin D3 supplementation in the elderly.

Authors:  C J Bacon; G D Gamble; A M Horne; M A Scott; I R Reid
Journal:  Osteoporos Int       Date:  2008-12-20       Impact factor: 4.507

Review 6.  Management of osteoporosis in geriatric populations.

Authors:  Diane L Schneider
Journal:  Curr Osteoporos Rep       Date:  2008-09       Impact factor: 5.096

7.  Latitude, socioeconomic prosperity, mobile phones and hip fracture risk.

Authors:  O Johnell; F Borgstrom; B Jonsson; J Kanis
Journal:  Osteoporos Int       Date:  2006-11-01       Impact factor: 4.507

Review 8.  Hormone therapy for the prevention of bone loss in menopausal women with osteopenia: is it a viable option?

Authors:  Mary H Hohenhaus; Kelly A McGarry; Nananda F Col
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review.

Authors:  L J Peppone; S Hebl; J Q Purnell; M E Reid; R N Rosier; K M Mustian; O G Palesh; A J Huston; M N Ling; G R Morrow
Journal:  Osteoporos Int       Date:  2009-12-04       Impact factor: 4.507

Review 10.  Effect of calcium supplementation on hip fractures.

Authors:  I R Reid; M J Bolland; A Grey
Journal:  Osteoporos Int       Date:  2008-02-20       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.